Assuntos
Antígenos de Plantas/uso terapêutico , Dessensibilização Imunológica/métodos , Hipersensibilidade/terapia , Peptídeos/uso terapêutico , Pólen/imunologia , Administração Sublingual , Adulto , Antígenos de Plantas/imunologia , Betula/imunologia , Europa (Continente) , Feminino , Seguimentos , Humanos , Hipersensibilidade/imunologia , Masculino , Pessoa de Meia-Idade , Peptídeos/imunologia , Qualidade de VidaRESUMO
BACKGROUND: An immunotherapy formulation consisting of 3 contiguous overlapping peptides (COPs) derived from Bet v 1, the major birch pollen allergen, showed good clinical tolerability in a previous phase I/IIa clinical trial. OBJECTIVES: We sought to evaluate the efficacy and safety of allergen-specific immunotherapy using 2 dose regimens of Bet v 1 COPs versus placebo in subjects with birch pollen-induced allergic rhinoconjunctivitis. METHODS: A randomized, double-blind, placebo-controlled phase IIb clinical trial was performed to assess the efficacy of Bet v 1 COP immunotherapy during the 2013 birch pollen season. Before the season, Bet v 1 COPs (50 and 100 µg in aluminum hydroxide) or placebo (saline and aluminum hydroxide) were administered as 5 subcutaneous injections to 239 adults with allergic rhinoconjunctivitis to birch pollen. Bet v 1 COPs at 25 or 50 µg were administered on day 1, and 50 or 100 µg was administered on days 8, 15, 29, and 57, respectively. Patients were monitored for adverse events during the treatment period and assessed for combined rhinoconjunctivitis symptom and medication scores, as well as quality of life. RESULTS: Rhinoconjunctivitis symptom and medication scores improved in both Bet v 1 COP-treated groups, reaching statistical significance over placebo in the 50-µg group (least squares mean, -0.23; 26% improvement; P = .015). Both active groups showed significant improvement in quality of life and nighttime nasal symptom scores, supporting the primary end point findings. Bet v 1 COP injections were well tolerated, with a higher frequency of systemic adverse events in the 100-µg group. CONCLUSION: Two months of preseasonal immunotherapy with 3 COPs derived from Bet v 1 at a 50-µg dose showed promising efficacy, small risk for systemic reactions, and immunomodulatory changes in this single-season, dose-finding, phase IIb trial in patients allergic to birch pollen.
Assuntos
Alérgenos/imunologia , Antígenos de Plantas/imunologia , Conjuntivite Alérgica/imunologia , Conjuntivite Alérgica/terapia , Dessensibilização Imunológica , Peptídeos/imunologia , Rinite Alérgica/imunologia , Rinite Alérgica/terapia , Adolescente , Adulto , Alérgenos/administração & dosagem , Antígenos de Plantas/administração & dosagem , Conjuntivite Alérgica/fisiopatologia , Dessensibilização Imunológica/efeitos adversos , Dessensibilização Imunológica/métodos , Feminino , Humanos , Imunoglobulina E/imunologia , Imunoglobulina G/imunologia , Masculino , Pessoa de Meia-Idade , Peptídeos/administração & dosagem , Testes de Função Respiratória , Rinite Alérgica/fisiopatologia , Resultado do Tratamento , Adulto JovemAssuntos
Antígenos de Plantas/química , Asma/terapia , Conjuntivite Alérgica/terapia , Dessensibilização Imunológica/métodos , Peptídeos/administração & dosagem , Rinite Alérgica/terapia , Adulto , Antígenos de Plantas/imunologia , Asma/imunologia , Conjuntivite Alérgica/imunologia , Feminino , Humanos , Esquemas de Imunização , Imunoglobulina E/sangue , Imunoglobulina G/sangue , Memória Imunológica , Injeções Subcutâneas , Pessoa de Meia-Idade , Peptídeos/efeitos adversos , Peptídeos/imunologia , Rinite Alérgica/imunologiaRESUMO
The purpose of this study was to analyze the potential of various types of biodegradable microspheres (MS) (i) to activate in vitro cell line-derived macrophages (RAW 264.7, Mphi), and primary peritoneal and bone marrow-derived mouse Mphi, to prolong the release and presentation of microencapsulated synthetic malaria antigens by Mphi after uptake of antigen-loaded MS, and (ii) to stimulate an immune response in mice against a microencapsulated synthetic malaria antigen. The MS were made of various types of poly(lactide-co-glycolide) (PLGA) or chitosan cross-linked with tripolyphosphate. PLGA, but not chitosan MS, were efficiently ingested by Mphi. Upon exposure to the various MS types, Mphi increased only the production of reactive oxygen intermediates (ROI), while the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), and the expression of cyclooxigenase-2 (COX-2), inducible NO synthase (iNOS), the cell surface markers MHC class I and II, and CD 86 remained unaffected. In vitro release of the microencapsulated antigen from PLGA50:50 MS followed a pulsatile pattern and extended over 14 weeks. This prolonged antigen release was also mirrored in the significantly prolonged antigen presentation over more than 7 days by Mphi after uptake of antigen-loaded PLGA MS. Finally, antigen-loaded PLGA MS induced a solid immune response in mice after a single s.c.-injection, which was only slightly inferior to the antibody titers measured with the control formulation with Montanide ISA720. These results suggest that MS are well tolerated by Mphi. The prolonged antigen presentation by Mphi, as measured in vitro, along with the capacity to induce a strong immune response in animals emphasize that biodegradable MS are a very promising delivery system for both preventive and immunotherapeutic vaccines.